Oxaloacetate Pharmacokinetics and Safety
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2014 |
| Start Date: | February 2014 |
| End Date: | February 2015 |
| Contact: | Rebecca Bothwell, MS |
| Email: | rbothwell@kumc.edu |
| Phone: | (913) 945-5033 |
By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the
blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's
disease who take OAA for one month have any side-effects.
blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's
disease who take OAA for one month have any side-effects.
Inclusion Criteria:
- Meet criteria for Mild or Moderate AD
- Have a study partner
- Speak English as primary language.
Exclusion Criteria:
- Absence of a study partner
- Report a potentially confounding, serious medical risk such as type 1 diabetes,
cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
We found this trial at
1
site
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
